Researchers involved in the clinical investigation of a new COVID-19 vaccine cited using HemaCare healthy donor starting materials for their study.
The scientists, most of whom work at ImmunityBio in Culver City, CA, are conducting a Phase 1 clinical trial for their new dual-antigen COVID-19 vaccine. [1]
A new publication by scientists at the Cell and Gene Therapy Catapult in the UK cites the use of HemaCare-sourced CD3+ T cells for their cancer immunotherapy research.
The successful commercialization of gene-modified cell therapies relies in part on being able to manufacture a consistent product. Many cell and gene therapy developers use lentiviral vector delivery systems to impart the therapeutic gene modifications necessary to making their therapies effective.
An independent publication cites the use of HemaCare-sourced PBMC as starting material for an assay designed to screen for factors that enhance anti-tumor cytotoxic T cell activity. [1]
The paper, published in the renowned scientific journal Nature, reports the study results of a scientific team working at Novartis in San Diego. Their goal is to develop a discovery platform that more closely mimics the in-vivo tumor microenvironment.
The vaccine was designed to assist a patient’s immune system target brain tumors more effectively and efficiently.
Gliomas are brain cancers that are considered rare disorders that affect 6.6 out of 100,000 individuals yearly worldwide.
Cryptococcus fungi infections can be fatal as the immune system struggles to fight off the invaders, but through immunotherapy called CAR T cell therapy, researchers are seeing positive results.
Cryptococcosis, a systemic fungal infection, is caused by the polysaccharide encapsulated yeasts Cryptococcus gatti and Cryptococcus neoformans. The disease can cause pneumonia and meningitis, as well as pathology in other tissues.